OBJECTIVES: The CheckMate 067 trial demonstrated that NIVO+IPI and NIVO significantly improve progression-free survival (PFS) compared with IPI (median PFS was 11.5, 6.9, and 2.9 months, respectively); however little is known regarding the healthcare costs associated with these new therapies. The aim of this study was to compare the total melanoma-specific healthcare costs associated with these 3 alternatives in the European subset of advanced melanoma (AM) patients initiating first line (1L) treatment in CheckMate 067. METHODS: Data for patients recruited from all European countries in the trial were used to derive resource utilization (including drug, inpatient, outpatient, procedures, laboratory and emergency room costs), for the 3 treatments [(N = 177 (NIVO+IPI), 170 (NIVO), 167 (IPI)]. Unit costs were those from the UK setting. Drug costs were sourced from NHS drug tariff list, British National Formulary and other sources. All other costs were taken from the NHS Reference Costs. All melanoma-specific healthcare costs occurring during the first year of treatment, including before and after disease progression (defined by RECIST, v.1.1) during this period, were aggregated and adjusted for censoring. RESULTS: The total per patient melanoma healthcare costs during the first year of treatment for NIVO+IPI, NIVO, and IPI were £97K, £71K and £99K, respectively. Patients’ pre- and post-progression costs during this period were £84K and £13K for NIVO+IPI, £41K and £31K for NIVO and £65K and £34K for IPI. CONCLUSIONS: Total melanoma-specific healthcare costs were found to be slightly lower for NIVO+IPI and 28% lower for NIVO when compared with IPI. Total post-progression costs with NIVO+IPI were 63% lower vs IPI and 59% lower vs NIVO, reflecting the lower proportion of NIVO+IPI patients progressing and requiring subsequent treatment. These results suggest 1L AM patients may realize significant clinical benefit with NIVO+IPI and NIVO monotherapy vs IPI, while reducing melanoma-specific healthcare costs.